Clinical relevance of circulating cell-free microRNAs in ovarian cancer by unknown
REVIEW Open Access
Clinical relevance of circulating cell-free
microRNAs in ovarian cancer
Koji Nakamura, Kenjiro Sawada*, Akihiko Yoshimura, Yasuto Kinose, Erika Nakatsuka and Tadashi Kimura
Abstract
Ovarian cancer is the leading cause of death among gynecologic malignancies. Since ovarian cancer develops
asymptomatically, it is often diagnosed at an advanced and incurable stage. Despite many years of research, there
is still a lack of reliable diagnostic markers and methods for early detection and screening. Recently, it was discovered
that cell-free microRNAs (miRNAs) circulate in the body fluids of healthy and diseased patients, suggesting that they
may serve as a novel diagnostic marker. This review summarizes the current knowledge regarding the potential clinical
relevance of circulating cell-free miRNA for ovarian cancer diagnosis, prognosis, and therapeutics. Despite the high
levels of ribonucleases in many types of body fluids, most of the circulating miRNAs are packaged in microvesicles,
exosomes, or apoptotic bodies, are binding to RNA-binding protein such as argonaute 2 or lipoprotein complexes, and
are thus highly stable. Cell-free miRNA signatures are known to be parallel to those from the originating tumor cells,
indicating that circulating miRNA profiles accurately reflect the tumor profiles. Since it is well established that the
dysregulation of miRNAs is involved in the tumorigenesis of ovarian cancer, cell-free miRNAs circulating in body fluids
such as serum, plasma, whole blood, and urine may reflect not only the existence of ovarian cancer but also tumor
histology, stage, and prognoses of the patients. Several groups have successfully demonstrated that serum or plasma
miRNAs are able to discriminate patients with ovarian cancer patients from healthy controls, suggesting that the
addition of these miRNAs to current testing regimens may improve diagnosis accuracies for ovarian cancer. Furthermore,
recent studies have revealed that changes in levels of cell-free circulating miRNAs are associated with the condition of
cancer patients. Discrepancies between the results across studies due to the lack of an established endogenous miRNA
control to normalize for circulating miRNA levels, as well as differing extraction and quantification methods, are the
pitfalls to be resolved before clinical application. There is still a long way, however, before this can be achieved, and
further evidence would make it possible to apply circulating cell-free miRNAs not only as biomarkers but also as
potential therapeutic targets for ovarian cancer in the future.
Keywords: Circulating miRNA, Ovarian cancer, Serum, Plasma, Early detection
Background
Ovarian cancer is the leading cause of gynecological
cancer-associated deaths in developed countries. In the
United States, ovarian cancer is the fifth leading cause of
cancer death in females, with an estimated incidence of
14,180 deaths in 2015 [1]. High-grade serous ovarian can-
cer (HGSOC) accounts for 70–80 % of ovarian cancer
deaths. While this disease is termed an ovarian cancer, a
wide range of studies have suggested that secretory epithe-
lial cells of the distal fallopian tube are the likely progeni-
tors of a substantial proportion of HGSOCs, although
some HGSOCs arise without fallopian tube [2]. While the
survival rates of patients diagnosed with early stage ovar-
ian cancer are high, most cases are diagnosed at a late
stage with peritoneal dissemination. If diagnosed at an
early stage, the 5-year survival rate exceeds 90 %. How-
ever, in patients with stage III or IV ovarian cancer, despite
comprehensive treatments by aggressive cytoreductive
surgery and chemotherapy with platinum- and taxane-
based drugs, the 5-year survival rate remains at a dismal
30 % [1]. This high mortality rate of ovarian cancer is as-
sociated with the difficulties of early detection, because it
is usually asymptomatic until late stage. Efficient early
detection procedures have yet to be established. Although
pelvic examination, transvaginal ultrasonography, and serum
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carbohydrate antigen 125 (CA125) are usually performed
as routine diagnostic procedures for ovarian cancer, their
diagnostic values are limited due to lack of the sensitivity
and specificity [3]. For example, CA125 is only elevated in
50–60 % patients with stage I and II ovarian cancer [4]. In
the retrospective study with 751 females, the sensitivity of
CA125 for ovarian cancer at all stages was 88.6 %, but
with a specificity of only 72.0 % [4]. In the recent study
with 118 patients with ovarian cancer, 84 with benign dis-
ease, and 61 healthy females, the sensitivity and specificity
of CA125 were 77.4 and 70.8 %, respectively [5]. There-
fore, development of novel approaches to effectively detect
ovarian cancer at an early, curable stage is urgently re-
quired. Another cause of this high mortality rate is the re-
sistance to chemotherapy, especially in recurrent cases.
Although ovarian cancer is highly responsive to the initial
treatment by platinum- and taxane-based chemotherapies,
subsequent relapses and repeated treatments using these
cytotoxic chemotherapies eventually result in acquired re-
sistance to the treatments. Therefore, most patients who
experience cancer relapse eventually succumb to the dis-
ease [6]. In the last decade, a variety of targeted therapies
have been developed to target the cancer-specific genes
and proteins or the tumor microenvironment that con-
tributes to cancer growth and maintenance. Among the
new drugs studied for ovarian cancer, bevacizumab, an
anti-vascular endothelial growth factor (VEGF) antibody,
has shown promising activities in combination with stand-
ard chemotherapies in large Phase III trials [7, 8]. How-
ever, no significant benefits with respect to overall survival
have been reported so far. Poly ADP ribose polymerase
(PARP) inhibitors, which lead to formation of extensive
double-stranded DNA breaks that cannot be accurately
repaired in tumors, have shown potential for improved
survival. Olaparib, a potent oral PARP inhibitor, signifi-
cantly improved progression-free survival in patients with
platinum-sensitive, relapsed, high-grade serous ovarian
cancer; however, interim analysis showed no overall sur-
vival benefit [9]. Therefore, definitive treatments that sub-
stantially extend overall patient survival have yet to be
established [10]. This is partly due to the lack of methods
to discriminate between patients who will or will not
benefit from the specific molecular targeted treatments.
Thus, identification of useful clinical biomarkers to predict
possible resistance to each treatment and prognoses of
cancer patients would greatly benefit the management of
ovarian cancer treatment [11]. Accumulating evidence has
revealed that microRNAs (miRNA or miR) are extensively
involved in cancer progression and suppression by regu-
lating thousands of cancer-associated genes [12]. miRNAs
can stably exist not only in cytoplasm, but also in various
types of body fluids. Circulating cell-free miRNAs have
been shown to have the potential to enable earlier
cancer diagnosis and to predict prognosis and response to
therapy [13]. This review summarizes the cumulative ef-
forts in the field of circulating miRNAs focusing on their
potential as novel biomarkers in ovarian cancer.
miRNAs and ovarian cancer
miRNAs are endogenously expressed, single-stranded
non-coding RNAs that are typically 19–25 nucleotides
in length. They are initially generated as long primary
miRNAs (pri-miRNAs) by RNA II polymerase-mediated
transcription in the cell nucleus. The primary miRNAs
are cleaved into approximately 70 nucleotide-long pre-
cursor miRNAs, which are subsequently transported into
the cytoplasm and further cleaved into mature miRNAs
[14]. miRNAs predominantly act as transcriptional re-
pressors by binding the 3’ untranslated region of their
target messenger RNAs. It is well established that miR-
NAs are key regulators of post-transcriptional gene ex-
pression [14, 15]. In mammals, miRNAs are estimated to
control the activities of more than 50 % of all protein-
coding genes [16] and have been shown to be involved
in the regulation of almost all cellular processes [17].
Drosha and Dicer are essential enzymes for the biogen-
esis of miRNA. Drosha, an RNase III enzyme, cleaves
the pri-miRNA and releases a hairpin-structured pre-
miRNA in the nucleus. After the pre-miRNA is exported
into the cytoplasm, Dicer, another RNase III enzyme,
cleaves the pre-miRNA and releases the miRNA du-
plexes. In ovarian cancer patients, low Dicer expression
is significantly correlated with advanced stage ovarian
cancer, and low Drosha expression with suboptimal sur-
gery [18], suggesting that impaired processing of miRNAs
by Dicer and Drosha is involved in the tumorigenesis of
ovarian cancer, and it leads to poor clinical outcomes [19].
Many studies have shown that dysregulation of miRNAs is
involved in a variety of human diseases including ovarian
cancer [19, 20]. The Cancer Genome Atlas (TCGA) pro-
ject analyzed mRNA expression, miRNA expression, pro-
moter methylation, and DNA copy number in a total of
489 HGSOCs and showed that ovarian cancers could be
separated into 3 miRNA subtypes [21]. Among these, a ro-
bust integrated mesenchymal subtype was associated with
poor survival, and eight key miRNAs (miR-25, miR-29c,
miR-101, miR-128, miR-141, miR-182, miR-200a, and
miR-506) were identified [22]. Mining the TCGA data,
Miles et al. identified 17 miRNAs that were dysregulated
in HGSOCs in comparison with normal ovary samples, in-
cluding eight upregulated miRNAs (miR-183-3P, miR-
15b-3p, miR-15b, miR-590-5p, miR-18a, miR-16, miR-96,
and miR-18b) and nine downregulated miRNAs (miR-
140-3p, miR-145-3p, miR-143-5p, miR-34b-5p, miR-145,
miR-139-5p, miR-34c-3p, miR-133a, and miR-34c-5p)
[23, 24]. Emerging evidence has revealed the role of
microRNAs in ovarian cancer as oncogenes or tumor sup-
pressor genes. For instance, Ohyagi-Hara et al. identified
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that miR-92a inhibits peritoneal dissemination of ovarian
cancer cells by inhibiting integrin α5 expression, which
had previously been shown as a key molecule in peritoneal
dissemination [25, 26]. Kinose et al. demonstrated that
miR-199a-3p is downregulated in high-grade serous ovar-
ian carcinomas, and the loss of miR-199a-3p is involved in
ovarian carcinogenesis and peritoneal dissemination by
causing the upregulation of c-Met, a receptor against hep-
atocyte growth factor [27]. Davidson et al. and Zhang et
al. summarized the roles of miRNAs in ovarian cancer in
their review papers [24, 28].
miRNAs in circulation
Since high levels of endogenous nucleases are present in
body fluids, freely circulating RNAs were expected to be
rapidly degraded. However, recent evidence has revealed
that miRNAs are secreted from cells into circulation
where they exist stably, and sometimes can be function-
ally transferred to recipient cells [29, 30]. Circulating
miRNAs were first detected in the serum and plasma
[31, 32] in 2008, and subsequently found in a variety of
body fluids, such as saliva, urine, breast milk, and so on
[33–58] (Fig. 1). One of the first studies measuring
miRNA levels in the serum was reported by Mitchell et
al. [31], who found that miRNAs are present in human
plasma in a remarkably stable form that is protected
from endogenous RNase activity. They could distinguish
patients with prostate cancer from healthy subjects by
measuring the serum levels of miR-141. In 2009, Park
NJ, et al. reported that endogenous salivary miRNAs
were degraded at much slow rates compared with ex-
ogenous miRNA, and that both miR-125a and miR-200a
were present at significantly lower levels in the saliva of
oral squamous cell carcinoma patients than in control
subjects, indicating the presence of miRNA in saliva
[46]. Currently, circulating miRNAs are known to be re-
markably stable under harsh conditions, such as extreme
pH values, high temperatures, and long-term storage
[31, 32, 56]. Current studies have suggested that miR-
NAs are released from cells into circulation by using
several packaging and transportation systems to avoid
degradation (Fig. 2): (a) Active secretion: miRNAs are
encapsulated in extracellular membrane vesicles such as








Oral cancer miR-125a, miR-200a [46]
Lung cancer miR-198 [35]
Cervical cancer  miR-21, miR-146a [40]
Pancreatic cancer miR-940, miR-3679-5p [48]
Esophageal cancer miR-10b-3p, miR-21,
miR-144, miR-451 [47]
Malignant pleural mesothelioma 
let-7a, miR-125a-5p, miR-320, miR-484 [37]
Serosa-invasive gastric cancer 
miR-21, miR-1225-5p [39]
Bladder cancer  miR-106b [42]
Bladder cancer  miR-99a, miR-125b [43]
Bladder cancer  miR-155, miR-21, miR-125b, miR-451 [44]
Prostate cancer miR-484, miR-1825 [45]
Ovarian cancer miR-30-5p [41]
Lung cancer miR-22, miR-134, miR-185 [36]
Colorectal cancer miR-7, miR-93, miR-409-3p [56]
Cervical cancer miR-218 [53]
Thyroid cancer let-7e, miR-151-5p, and miR-222 [54]
Renal cell cancer miR-378, miR-451 [55]
Breast cancer miR-148-3p, miR-652-3p [57]
cerebrospinal fluid 
Glioblastoma miR-21 [34]
PCNSL miR-19, miR-21, miR-92a [33]
NSCLC miR-21, miR-148a, miR-148b, miR-152 [58]
Gastric cancer  miR-1, miR-20a, miR-27a, 
miR-34, miR-423-5p [51]
Malignant melanoma miR-221 [52]
Ovarian cancer mIR-21, miR-23b, miR-29a [38]
miR-335-3p, miR-26a-2-3p, miR-181d [49]
Ovarian cancer miR-21, miR-141, miR-200a, 
miR-200b, miR-200c, miR-203, miR-205, 
miR-214 [50]
Fig. 1 miRNAs in various human body fluids. miRNAs can be detected in various human body fluids. Circulating miRNAs reported as potential
non-invasive diagnostic markers for many types of cancers are shown. miRNAs which were reported to be upregulated in cancer patients compared
to controls (healthy or benign) are shown in red, and those downregulated in cancer patients are shown in blue. In [39], miR-21 and miR-1225-5p were
overexpressed in ascites from serosa-invasive gastric cancer patients compared with non-invasive gastric cancer patients. In breast milk, 3 most
abundant miRNAs are listed in the figure. PCNSL: primary central nervous system lymphoma; NSCLC: non-small cell lung cancer
Nakamura et al. Molecular Cancer  (2016) 15:48 Page 3 of 10
[29, 59]. They are also secreted via binding to miRNA-
binding proteins, such as AGO2, or serum lipid carriers,
such as HDL [60, 61]. (b) Passive leakage: miRNAs are
involved in shedding vesicles, such as apoptotic bodies
(−4000 nm), as a result of apoptotic death [62]. Previous
studies have demonstrated that miRNA expression pro-
files are different depending on the physiological and
pathological conditions [63]. In other words, some miR-
NAs are upregulated or downregulated specifically in
certain cancer types. This stability and specificity make
circulating miRNAs potential biomarkers of cancer diag-
nosis [13].
Methodologies for the collection and analysis of
circulating miRNAs
The expression profile of circulating miRNAs is highly
affected by the methodologies of sample preparation [60,
64]. How to prepare samples adequately depends on the
types of body fluids. In ovarian cancer research, samples
were generally collected from blood, ascites, or urine.
Blood samples were firstly processed into serum or
plasma in most studies. For urine analyses, morning
whole-stream urine samples were collected [41]. Ascites
was collected for routine diagnostic purposes during
gynecological surgeries or abdominocentesises. There-
after, they were centrifuged to avoid contamination of
cell fraction and stored in −80 °C [41, 65–80]. In exoso-
mal miRNA research, exosomes were collected using an
ultracentrifugation method or a commercial-based exo-
some isolation kit such as ExoQuick (SBI, Palo Alto,
CA) [30, 50]. Thereafter, the extraction of RNA is
usually performed by using commercially available
techniques including phenol/guanidinium products, such
as TRIzol (Life Technologies), and column-based extrac-
tion kits, such as mirVana (Life Technologies) and miR-
Neasy (QIAGEN).
In most studies, the extracted miRNAs are subjected to
next-generation sequencing (NGS) or miRNA microarrays
to obtain large-scale profiles of circulating miRNAs and
determine candidate miRNAs for further quantification.
Each method has certain advantages and limitations. NGS
has a potential to identify novel miRNAs but is less cost-
effective and less efficient compared with microarrays.
Thereafter, the candidate miRNAs are generally subjected
to further validation by quantitative reverse transcription
polymerase chain reaction (qRT-PCR) in larger cohorts.
Establishment of endogenous controls for miRNA nor-
malization remains the bottleneck for the reliable quantifi-
cation of miRNAs. While RNU-6B, RNU-48, and miR-16
are commonly used as endogenous controls, no definitive
control gene has been established [13, 81]. Recent studies
have suggested more reliable endogenous controls for the
quantification of circulating miRNAs [82, 83]. Chen et al.
reported that a combination of let-7d, let-7 g and let-7i
serves as an endogenous control of serum miRNAs
and it is superior to the commonly used reference
genes [82]. Kok et al. suggested normalization panels
for the better quantification of circulating microRNAs
by RT-qPCR [83]. Further studies with a large num-
ber of samples would be needed to determine a suit-
able reference for reliable normalization of circulating
miRNAs.
extracellular vesicles
















Fig. 2 Circulating miRNAs derived from ovarian cancer. Ovarian cancer-associated miRNAs are reported to be detected from blood (serum/
plasma), urine, or ascites. MiRNAs in circulation display remarkable stability. They are encapsulated by membrane-enclosed vesicles such as
exosomes and microvesicles, or bound to carrier protein or lipids such as Argonaute2 (Ago2) and HDL. miRNAs are protected by these miRNA-
carriers from RNase in circulation [29, 59–62]. HDL: high density lipoprotein
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Clinical relevance of cell-free miRNAs in ovarian
cancer
Since 2008, numerous studies have demonstrated the
clinical relevance of circulating miRNAs as diagnostic
and prognostic biomarkers for a variety of cancer types,
using blood plasma or serum. Cancer-associated circu-
lating miRNA expression profiles were determined and
have been shown to be related to tumor development,
disease progression, and metastases. This section de-
scribes the potential roles of circulating miRNAs as novel
biomarkers in regard to diagnosis and prognosis in ovar-
ian cancer.
1. Diagnostic potential of circulating miRNAs in
ovarian cancer
Approximately 20 studies have been published on
the diagnostic potential of circulating miRNAs in
ovarian cancer. Taylor et al. first reported that eight
exosomal miRNAs (miR-21, miR-141, miR-200a,
miR-200b, miR-200c, miR-203, miR-205, and miR-214)
from sera were elevated in ovarian cancer patients
compared to benign controls, which had been
reported to be overexpressed in ovarian cancer tissues.
These miRNAs were overexpressed even in patients
with early stages of ovarian cancer. The miRNA
signatures from exosomes were parallel to those from
the originating tumor cells, indicating that circulating
miRNA profiles accurately reflect the tumor profiles
[50]. Following this study, various reports have
demonstrated the diagnostic potential of circulating
miRNAs in body fluids such as serum, plasma, whole
blood, and urine [41, 65–80] as summarized in Table 1.
Hauser et al. investigated the miRNA expression
pattern in relapsed ovarian cancer patients from
whole blood samples containing cellular fraction by
miRNA array. They reported that miR-30c-1-3p was
upregulated, and miR-342-3p, miR-181a-3p, and miR-
450b-5p were downregulated in patients with relapsed
ovarian cancer when compared to healthy controls
[66]. Kan et al. reported that the expression levels of
Table 1 Circulating miRNAs as potential diagnostic biomarkers of ovarian cancer





Serous Others I-II III-IV HC Ben Bor
[50], 2008 miR-21, miR-141, miR-200a, miR-200b,
miR-200c, miR-203, miR-205, miR-214
Serum
(exosome)
50 20 30 10 10
[65], 2009 miR-21, miR92, miR-93, miR-126,miR-29a miR-155, miR-127, miR-99b Serum 17 11 10 18 15
[66], 2010 miR-30c-1 miR-342-3p, miR-181a,
miR-450-5p
Whole blood 21 3 Relapsed 15
[67], 2012 miR-182, miR-200a, miR-200b, miR-200c Serum 28 1 27 28
[68], 2013 miR-132, miR-26a, let7-b,
miR-145
Serum 18 3 14 12
[69], 2013 miR-205 let-7f Plasma 179 181 133 227 200
[70], 2013 miR-16, miR-21, miR-191 (EAOC) miR-16,
miR-191, miR-4284 (SOC)
Plasma 21 14 12 23 20 33
[71], 2013 miR-21 Serum 68 26 32 62 40
[72], 2013 miR-221 Serum 70 26 32 64 35





Plasma 18 0 6 12 24
[74], 2014 miR-1274a, miR-625-3p, miR-720 miR-106b, miR-126, miR-150,
miR-17, miR-20a, miR-92a
Plasma 42 6 36 23 36
[75], 2015 miR-7, miR-429 miR-25,miR-93 Serum 120 60 32 147 66
[41], 2015 miR-30-5p Urine 39 16 18 30 26
[76], 2015 miR-141, miR-200c Serum 16 58 54 20 50 19
[77], 2015 miR-145 Serum 18 64 31 63 135
[78], 2015 let-7i-5p, miR-122, miR-152,
miR-25-3p
Serum/plasma 20 6 19 25
[79], 2015 miR-200a, miR-200b, miR-200c Serum 70 33 37 70
[78], 2015 miR-200b Plasma 51 6 45 25 25
FIGO: International Federation of Gynecology and Obstetrics, EAOC; endometriosis associated ovarian carcinoma, SOC; serous ovarian carcinoma, HC; healthy
control, Ben; Benign control, Bor; borderline tumor
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four serum miRNAs including the miR-200 family
(miR-182, miR-200a, −200b, and -200c) were
significantly elevated in serous ovarian cancer patients
compared with healthy volunteers. They identified a
multivariate model combining miR-200b and miR-
200c that has good predictive power to discriminate
patients with serous ovarian cancer and healthy
controls (AUC= 0.784), and this model may have
utility as potential biomarkers of serous ovarian
cancer [67]. Chung et al. analyzed an miRNA array
using RNAs isolated from serum, tissue, and ascites
from serous ovarian cancer patients and a healthy
control, and identified five miRNAs (miR-132, miR-
26a, let-7b, miR-145, and miR-143) as the most
significantly downregulated miRNAs in the sera of
ovarian cancer patients with respect to those of the
control [68]. Zheng et al. evaluated plasma samples of
360 epithelial ovarian cancer patients and 200 healthy
controls and found higher expression of plasma miR-
205 and lower expression of let-7f in the ovarian
cancer patients. Combination of miR-205 and let-7f
together provided high diagnostic accuracy for
epithelial ovarian cancer (AUC= 0.831 (95 % CI, 0.772
to 0.880; sensitivity = 62.4 %, specificity = 92.9 %),
particularly in patients with stage I disease, indicating
that these two miRNA signatures could be used as
biomarkers of ovarian cancer detection, particularly
for stage I disease [69]. Suryawanshi et al. focused on
endometriosis-associated ovarian cancer (EAOC)
(endometrioid adenocarcinoma or clear cell
carcinoma) and revealed three plasma miRNAs, miR-
16, miR-191, and miR-195, all upregulated in
endometriosis, that could differentiate between
healthy and endometriosis cases with 88 % sensitivity
and 60 % specificity. They further showed that a
combination of miR-16, miR-21, and miR-191 could
differentiate between healthy and EAOC with 86 %
sensitivity and 85 % specificity and that miR-21, miR-
191, and miR-1975 together could distinguish between
EAOC and serous ovarian cancer with 86 % sensitivity
and 79 % specificity [70]. Zuberi et al. reported that
serum miR-200a is significantly upregulated in
mucinous adenocarcinomas compared with other
types of histology in 70 epithelial ovarian cancer
patients and at the highest AUC value, the sensitivity
and specificity of this miRNA relative expression were
80.6 and 73.5 %, respectively [79]. Meng et al. revealed
that serum levels of mR-25 and miR-93 were down-
regulated, while those of miR-7 and miR-429 were
upregulated in 180 epithelial ovarian cancer patients
compared with 66 healthy women. These four miRNA
signatures discriminated ovarian cancer patients from
healthy women with a high sensitivity and specificity:
93 and 92 %, respectively [75]. Zhou et al. reported
diagnostic value of urinary miRNAs in ovarian cancer.
They identified significant upregulation of miR-30a-5p
in the urine sample of ovarian cancer patients when
compared to healthy controls. They also identified
that miR-30a-5p was concentrated in exosomes from
ovarian cancer cell culture supernatant and urine
from ovarian cancer patients, supporting a pathway
for miR-30a-5p excretion into the urine [41].
Kapetanakis et al. showed that plasma miR-200b was
significantly more abundant in patients with ovarian
cancer than in those with benign tumors. They
suggested the potential role of miR-200b as a
complementary biomarker of CA125, because there
was no significant correlation between the distributions
of these markers [80].
2. Potential of circulating miRNAs in ovarian cancer as
prognostic biomarkers
Current management of ovarian cancer relies on
clinicopathological factors including tumor histology
and stage. Recent studies have revealed that changes
in the levels of circulating miRNAs are associated
with the prognosis of ovarian cancer patients
[38, 69, 71, 72, 74–77, 80], as summarized in Table 2.
Zheng et al. demonstrated that lower plasma let-7f
expression was significantly correlated with poor
progression-free survival (PFS) in 360 ovarian cancer
patients, particularly in stage III and IV cases. Cox
regression analysis revealed that plasma let-7f was an
independent prognostic indicator of ovarian cancer in
PFS [69]. Zhao et al. investigated the serum level of
miR-21 in a total of 94 epithelial ovarian cancer
patients. They showed that increased serum miR-21
expression was associated with advanced FIGO stage,
high tumor grade, and shortened overall survival
(OS), and that a high level of serum miR-21 expression
was an unfavorable prognostic factor independent of
other clinicopathological factors [71]. Vaksman et al.
studied miRNA expression in effusion-derived
exosomes. Exosomes were collected from 66 malignant
peritoneal and 20 pleural effusions obtained from a
total of 86 ovarian cancer patients with advanced
stages. They demonstrated that high levels of miR-21,
miR-23b, and miR-29a were associated with poor PFS
in univariate analyses. In addition, high expression of
miR-21 was correlated with poor OS in Cox regression
analysis [38]. Gao et al. investigated the diagnostic and
prognostic potential of serum miR-200c and miR-141,
which are members of the miR-200 family, in 74
ovarian cancer patients. Both miRNAs were
significantly overexpressed in ovarian cancer patients
compared to 50 healthy control. Patients with high
miR-200c levels achieved a significantly higher 2-year
survival rate, while the low miR-141 group showed a
significantly higher survival rate [76].
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Several research groups have studied the ability of
miRNAs to predict the sensitivity to treatment. Kapetanakis
et al. demonstrated the pre/post-treatment variations of
plasma miR-200b in ovarian cancer as a potential prog-
nostic predictor. Plasma samples were collected from a
total of 33 ovarian cancer patients prior to and after pri-
mary treatment including surgery and chemotherapy.
CA125 returned to normal plasma concentrations within
the first month of treatment in almost all patients even in
the cases with unresectable tumor, whereas there was a re-
markable mix of variation in the concentrations of plasma
miR-200b. The patients with a negative miR-200b vari-
ation had a longer PFS than those patients with a positive
variation, and the risk of disease-progression was signifi-
cantly higher in patients with a positive variation of miR-
200b compared to those with a negative variation [80].
Benson et al. conducted a pilot study to identify plasma
miRNAs that can predict outcomes of a specific chemo-
therapy regimen: carboplatin with decitabine, a hypo-
methylating agent. Plasma samples were collected from 14
recurrent platinum-resistant ovarian cancer patients prior
to and at the end of the first cycle of treatment, and the
changes in plasma miRNA concentrations were evaluated.
Lower concentrations of circulating plasma miR-148b-5p
were associated with worse PFS, suggesting its potential as
a novel biomarker of therapeutic response [84].
Can circulating miRNA predict the response to
novel cancer treatments?
While a variety of molecular targeted therapies (e.g. beva-
cizumab, olaparib, or cediranib (a pan-VEGFR inhibitor)
[85] have been developed for ovarian cancer treatment
and showed some improvements in progression-free sur-
vival of patients, no significant benefits with respect to
overall survival have been reported so far [7–10, 85]. This
is partly due to the lack of methods to discriminate be-
tween patients who will or will not benefit from these
novel treatments. Since these therapies would be applied
mainly for relapsed ovarian cancer patients and it would
not be practically possible to obtain tumors in most re-
lapsed cases, the identification of novel biomarkers from
body fluids such as serum, plasma, whole blood, and urine
would be indispensable especially to those patients. Thus,
circulating cell free miRNAs in body fluids are to be
good candidates and need to be extensively analyzed. At
present, there have been no reports which showed the
association between these novel drugs and circulating
miRNAs in ovarian cancer; however, the recent study in
metastatic colorectal cancers revealed that changes in cir-
culating plasma miR-126 during treatment were predictive
of tumor response to the first-line chemotherapy (XELOX;
capecitabine and oxaliplatin) combined with bevacizumab
[86]. While the responding patients had a significant de-
crease of circulating miR-126, this circulating miRNA
modestly increased in non-responding patients. MiR-126
is known to have a high endothelial cell (EC) specificity
and involved in EC proliferation, migration, survival, and
in the regulation of blood vessel integrity [87, 88], indicat-
ing that the circulating level of this miRNA may reflect
the response to bevacizumab. Such efforts would be taken
in ovarian cancer treatment in the near future.
Can circulating miRNAs be therapeutic targets for
cancer treatment?
He WA, et al. reported cancer-secreted microvesicles con-
tain an elevated expression of miR-21 and induce myo-
blast apoptosis, which lead to cancer cachexia of patients
via a Toll-like receptor 7 (TLR7) [89]. They provided in-
sights into therapeutic avenues for cachexia, possibly by
inhibiting microvesicles secretion, inhibiting fusion of
microvesicles with muscle cells, or blocking the binding of
miR-21 to TLR7/8. Ciravolo et al. reported that the exo-
somes released by the HER2-overexpressing breast cancer
cell lines express a full-length HER2 molecule and that
Table 2 Circulating miRNAs as potential prognostic predictors of ovarian cancer
Reference miRNAs associated with poor prognosis Endpoint Source Patients (n) Histology (n) FIGO stage (n)
Increased miRNAs Decreased miRNAs Serous Others I-II III-IV
[69], 2013 let-7f PFS Plasma 360 179 181 133 227
[71], 2013 miR-21 OS Serum 94 68 26 32 62
[72], 2013 miR-221 OS Serum 96 70 26 32 64
[74], 2014 miR-1290 OS Plasma 26 26 0 6 36
[38], 2014 miR-21,miR-23b,
miR-29a (PFS), miR-21(OS)
PFS/OS Effusion (exosome) 86 76 10 0 86
[75], 2015 miR-429 OS Serum 180 180 32 147
[76], 2015 miR-141 miR-200c OS Serum 74 16 58 54 20
[77], 2015 miR-145 OS Serum 82 18 64 31 53
[80], 2015 miR-200b PFS Plasma 33 33 Unknown
FIGO: International Federation of Obstetrics and Gynecology, PFS: progression free survival, OS: overall survival
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these exosomes bound to trastuzumab and inhibited its
anticancer cell proliferative activity [90]. Based on this
preclinical data, Aethlon Medical Inc. (CA, USA) has de-
veloped HER2osome™, as a therapeutic strategy to combat
HER2 positive breast cancer through the capture of circu-
lating HER2-positive exosomes [91]. Although promising
results from these novel devices in the clinical settings
have not been reported so far, such approaches to elimin-
ate circulating microvesicles containing miRNAs have the
potential to be a breakthrough in cancer therapy.
Conclusions
In recent years, emerging evidence has suggested that
circulating miRNAs may hold great potential as promis-
ing biomarkers for early detection, prognosis, and sensi-
tivity to chemotherapy of ovarian cancer. However, to
date, most of the studies appear to be preliminary, be-
cause they simply identified altered levels of circulating
miRNAs in ovarian cancer patients with relatively small
cohort sizes. They lack direct comparison or in combin-
ation with conventional diagnostic procedures, such as
CA125 and ultrasonography, particular for early stage
diseases. In addition, the lack of standardized protocols
including sample collection, RNA extraction, and the se-
lection of suitable internal control makes it difficult to
compare the results between studies reported. There have
been inconsistent findings about circulating miRNAs from
the same tumor reported by different studies. Neverthe-
less, circulating miRNAs have potential as novel non-
invasive and highly useful biomarkers of ovarian cancer, as
shown in various types of disease such as cardiovascular
disease, diabetes mellitus, and cancer of other organs [92].
Further studies with standardized procedures and at larger
scales are warranted to enhance the consideration of the
clinical significance of circulating miRNAs in ovarian can-
cer. Recently several big projects focusing on circulating
miRNAs as a biomarker have launched. For instance, NIH
launched the Extracellular RNA Communication program
to advance the field of extracellular miRNA research in
2013. The NIH Common Fund awarded approximately
$130 million to 30 research projects to investigate the
diagnostic and therapeutic potential of circulating miR-
NAs [93]. In Japan, a big project led by the New Energy
and Industrial Technology Development Organization
(NEDO), a national research agency, started in 2014. This
project aims to enable the early detection of 13 types of
cancers including ovarian cancer using circulating miR-
NAs from blood samples of 65,000 people [94]. These
projects may be great milestones to establish miRNA-
based ovarian cancer detection. In addition, several basic
research studies have demonstrated that circulating miR-
NAs can be mediators of cell-to-cell communication dur-
ing cancer progression [89, 95, 96]. There is still a long
way, however, and further evidence would make it possible
to use circulating miRNAs not only as biomarkers but also
as potential therapeutic targets in the future.
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